Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Background: In this study, we describe the epidemiological profile of an outbreak of the circulating Vaccine Derived Polio Virus type 2 in South Sudan from 2020 to 2021.
Method: We conducted a retrospective descriptive epidemiological study using data from the national polio/AFP surveillance database, the outbreak investigation reports, and the vaccination coverage survey databases stored at the national level.
Results: Between September 2020 and April 2021, 59 cases of the circulating virus were confirmed in the country, with 50 cases in 2020 and 9 cases in 2021. More cases were males (56%) under five (93%). The median age of the cases was 23.4 ± 11.9 months, ranging from 1 to 84 months. All states, with 28 out of the 80 counties, reported at least one case. Most of the cases (44, 75%) were reported from five states, namely Warrap (31%), Western Bahr el Ghazal (12%), Unity (12%), Central Equatoria (10%), and Jonglei (10%). Four counties accounted for 45.8% of the cases; these are Gogrial West with 12 (20%), Jur River with 5 (8.5%), Tonj North with 5 (8.5%), and Juba with 5 (8.5%) cases. The immunization history of the confirmed cases indicated that 14 (24%) of the affected children had never received any doses of oral polio or injectable vaccines either from routine or during supplemental immunization before the onset of paralysis, 17 (28.8%) had received 1 to 2 doses, while 28 (47.5%) had received 3 or more doses (Fig. 4). Two immunization campaigns and a mop-up were conducted with monovalent Oral Polio Vaccine type 2 in response to the outbreak, with administrative coverage of 91.1%, 99.1%, and 97% for the first, second, and mop-up rounds, respectively.
Conclusion: The emergence of the circulating vaccine-derived poliovirus outbreak in South Sudan was due to low population immunity, highlighting the need to improve the country's routine and polio immunization campaign coverage.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10664300 | PMC |
| http://dx.doi.org/10.1186/s12879-023-08758-z | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Community-directed treatment with ivermectin in Maridi, South Sudan: Impact of an onchocerciasis awareness campaign and bi-annual treatment on therapeutic coverage.
PLoS Negl Trop Dis
September 2025
Global Health Institute, University of Antwerp, Antwerp, Belgium.
Background: A high onchocerciasis disease burden and a low coverage of community-directed treatment with ivermectin (CDTI) have been observed in many parts of South Sudan. In the Maridi County, CDTI was re-introduced in 2017 and various interventions implemented to improve coverage.
Methods: Through successive community-based surveys, we investigated whether an onchocerciasis awareness campaign and a switch from annual to bi-annual distribution of ivermectin in Maridi County increased CDTI coverage.
Assaulting Medical Neutrality: Reflections on Attacks on Healthcare and Clinicians in the Two World Wars and Implications for Contemporary Conflicts.
Nurs Inq
October 2025
School of Health Sciences, South East Technological University, Waterford, Ireland.
Wars in Ukraine, Sudan and the Middle East highlight that armed conflict is once more a significant geopolitical challenge across the world. An aspect of such wars is the deliberate violation of medical neutrality through the targeting of hospitals and clinical staff, including nurses, in breach of international law. Through a narrative review of documented cases, this article reflects on recurring themes in attacks on medical neutrality during the World Wars that resonate with contemporary wars.
View Article and Find Full Text PDFGlobal policy responses to antimicrobial resistance, 2021-22: a systematic governance analysis of 161 countries and territories.
Lancet Infect Dis
September 2025
Global Health Governance Programme, Usher Institute, University of Edinburgh, Edinburgh, UK.
Background: Most countries have endorsed a national action plan (NAP) on antimicrobial resistance. We previously used a governance framework to assess NAPs on antimicrobial resistance available for the period of 2020-21 from 114 countries, finding substantial variation worldwide in the commitment of resources to address an escalating global health challenge. We sought to expand and advance this analysis to include the NAPs of more low-income and middle-income countries, to cover the period of 2021-22, and to examine the strength of NAPs to address antimicrobial resistance.
View Article and Find Full Text PDFUse of fexinidazole in gambiense human African trypanosomiasis: a retrospective analysis of cases treated in Lui Hospital, South Sudan (2018-2024).
Infection
September 2025
Doctors with Africa CUAMM, Padua, Italy.
Purpose: Fexinidazole, an oral molecule, replaced pentamidine and combined treatment with nifurtimox and eflornithine (NECT) therapy for stage 1 and non-severe stage 2 gambiense human African Trypanosomiasis (g-HAT), respectively. The study aims to evidence differences of outcome at discharge and adverse drug reactions (ADRs) between fexinidazole and pentamidine/NECT regimens in patients with stage 1 and non-severe stage 2 g-HAT admitted to Lui Hospital (Western Equatoria, South Sudan), a historical g-HAT focus.
Methods: Data of patients (n = 86) admitted to Lui Hospital from July 2018 to June 2024 with g-HAT diagnosis were included.
Effects of Stop-Work orders on HIV testing, treatment and programmes for prevention of vertical transmission in four sub-Saharan African countries.
J Int AIDS Soc
September 2025
ICAP at Columbia University, New York, New York, USA.
Introduction: Beginning in late January 2025, Stop-Work orders and contract cancellations have disrupted HIV programmes supported by the President's Emergency Plan for AIDS Relief (PEPFAR). We assessed the effects on HIV service delivery in four African countries.
Methods: Weekly aggregate HIV services data from a convenience sample of 165 Center for Disease Control and Prevention (CDC)-funded, ICAP-supported facilities-22 in Angola, 75 in the Democratic Republic of the Congo (DRC), 20 in South Sudan and 48 in Zambia-were analysed.